Canget BioTekpharma LLC is a biotechnology and biopharmaceutical company that specializes in developing innovative cancer-targeting agents with a focus on minimizing toxicity to normal tissues while maximizing efficacy against cancer cells. The company emerged from the Roswell Park Cancer Institute and aims to address significant challenges in cancer treatment, such as drug toxicity, resistance to therapies, and cancer metastasis. Canget's mission is to enhance cancer patient survival rates by creating highly effective, low-toxicity anticancer agents that can overcome drug resistance and prevent tumor relapse.

One of the key technologies developed by Canget is FL118, a novel small molecule that has shown exceptional efficacy against advanced and treatment-resistant tumors, particularly pancreatic and colorectal cancers. FL118 operates through a unique mechanism that does not rely on topoisomerase I, a common target for many existing chemotherapeutics, which often leads to high toxicity. Instead, FL118 selectively inhibits the expression of several oncogenic proteins, including survivin and Mcl-1, and is not affected by common drug resistance mechanisms, such as efflux pump proteins. This innovative approach positions FL118 as a promising candidate for personalized cancer therapy, particularly for patients with specific genetic profiles that indicate sensitivity to the drug.

United States

Canget BioTekpharma is a biotech and biopharma company used to develop novel, cancer-targeting anticancer agents.

Canget BioTekpharma

Company Details